Mary Flack

2.1k total citations · 2 hit papers
25 papers, 1.5k citations indexed

About

Mary Flack is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Mary Flack has authored 25 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 11 papers in Dermatology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Mary Flack's work include Psoriasis: Treatment and Pathogenesis (13 papers), Dermatology and Skin Diseases (7 papers) and Autoimmune Bullous Skin Diseases (3 papers). Mary Flack is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (13 papers), Dermatology and Skin Diseases (7 papers) and Autoimmune Bullous Skin Diseases (3 papers). Mary Flack collaborates with scholars based in United States, Germany and Canada. Mary Flack's co-authors include Kim Papp, Andrew Blauvelt, Melinda Gooderham, Howard Sofen, Yihua Gu, James G. Krueger, Elizabeth H. Thompson, Ziqian Geng, Mamitaro Ohtsuki and Joaquin Valdes and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Allergy and Clinical Immunology.

In The Last Decade

Mary Flack

22 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

2018 452 citations Kenneth B. Gordon, Bruce Strober et al. The Lancet profile →
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

2017 392 citations Kim Papp, Andrew Blauvelt et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Mary Flack

Since Specialization

Citations

This map shows the geographic impact of Mary Flack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Flack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Flack more than expected).

Fields of papers citing papers by Mary Flack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Flack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Flack. The network helps show where Mary Flack may publish in the future.

Co-authorship network of co-authors of Mary Flack

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Flack. A scholar is included among the top collaborators of Mary Flack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Flack. Mary Flack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis 2025 ·Journal of Investigative Dermatology ·Melinda Gooderham, Ulrich Mrowietz, (unknown), (unknown), Hui Gu, (unknown), Mary Flack, (unknown), Howard Sofen, Kim Papp	1
2	Bounded integer model‐based analysis of psoriasis area and severity index in patients with moderate‐to‐severe plaque psoriasis receiving BI 730357 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Anders Kristoffersson, (unknown), Mary Flack, Elodie L. Plan, Benjamin Weber	8
3	The Effect of BI 730357 (Retinoic Acid‐Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open‐Label, Non‐randomized, 2‐Period Fixed‐Sequence Trial in Healthy Subjects 2023 ·Clinical Pharmacology in Drug Development ·(unknown), Fenglei Huang, Mary Flack	5
4	AB0877 TARGETING VASCULOPATHY TO SLOW FIBROSIS IN SYSTEMIC SCLEROSIS (SSC): DESIGN OF A PHASE II STUDY WITH A SOLUBLE GUANYLATE CYCLASE ACTIVATOR (SGCA) 2023 ·Annals of the Rheumatic Diseases ·Dinesh Khanna, Mary Flack, Tobias Litzenburger, Nora Fagan, Oliver Distler	0
5	The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry 2022 ·PubMed ·Mark Lebwohl, Rose Anne Medeiros, Rachel H. Mackey, Leslie R. Harrold, Wendell C. Valdecantos, Mary Flack, Amanda Golembesky, (unknown), Bruce Strober	15
6	Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial 2021 ·Dermatology and Therapy ·Kim Papp, (unknown), Jiewei Zeng, Mary Flack, (unknown), Stephen K. Tyring	8
7	25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry 2021 ·Journal of the American Academy of Dermatology ·Mark Lebwohl, (unknown), Rose Anne Medeiros, Nicole C. Foster, (unknown), Wendell C. Valdecantos, Mary Flack, Amanda Golembesky, Bruce Strober	1
8	Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists 2021 ·Dermatology and Therapy ·Bruce Strober, (unknown), Rose Anne Medeiros, Rachel H. Mackey, Leslie R. Harrold, Wendell C. Valdecantos, Mary Flack, Amanda Golembesky, Mark Lebwohl	51
9	Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers 2020 ·British Journal of Clinical Pharmacology ·Tobias Litzenburger, Jürgen Steffgen, (unknown), Fabian Müller, Armin Schultz, Elliott Klein, Meera Ramanujam, Christian Harcken, (unknown), Jing Wu, Sabrina Wiebe, Xiujiang Li, Mary Flack, Steven J. Padula, Sudha Visvanathan, (unknown), Jianan Hui	4
10	Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial 2019 ·The Journal of Dermatology ·Mamitaro Ohtsuki, Hideki Fujita, Masao Watanabe, (unknown), Mary Flack, Xin Huang, Susumu Kitamura, Joaquin Valdes, Atsuyuki Igarashi	79
11	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial 2019 ·The Lancet ·Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey Crowley, Caitriona Ryan, James G. Krueger, Tsen‐Fang Tsai, Mary Flack, Yihua Gu, David Williams, Elizabeth H. Thompson, C. Paul	219
12	32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers 2019 ·Abstracts ·Tobias Litzenburger, Fabian Müller, Armin Schultz, Elliott Klein, Meera Ramanujam, Jing Wu, Sabrina Wiebe, (unknown), Jianan Hui, Xiujiang Li, Mary Flack, Steven J. Padula, Sudha Visvanathan, Jürgen Steffgen, (unknown)	1
13	EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS 2018 ·Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez	10
14	Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab 2018 ·Journal of Allergy and Clinical Immunology ·Sudha Visvanathan, Patrick Baum, Richard Vinisko, Ramona Schmid, Mary Flack, Bojan Lalovic, Oliver Kleiner, Judilyn Fuentes‐Duculan, Sandra Garcet, J. Wade Davis, Kristie M. Grebe, Jay S. Fine, Steven J. Padula, James G. Krueger	58
15	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials breakdown → 2018 ·The Lancet ·Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez	452
16	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis breakdown → 2017 ·New England Journal of Medicine ·Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula	392
17	Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens 2011 ·Vaccine ·Lawrence R. Stanberry, Jakub K. Simon, Casey Johnson, (unknown), Jingga Morry, Mary Flack, S. Gracon, Andrzej Myc, Tarek Hamouda, James R. Baker	53
18	Subject-Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis 2008 ·46th Annual Meeting ·Mary Flack	1
19	Acne Treatment with a Low-Dose Oral Contraceptive 2001 ·Obstetrics and Gynecology ·Melissa Gilliam, (unknown), Jennifer Maloney, Mary Flack, (unknown), (unknown), Richard J. Derman	1
20	Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol 2001 ·Contraception ·Rebecca A. Boyd, (unknown), Edward L. Posvar, Mary Flack	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact